PDCD1 and hepatocellular carcinoma: Actually, with the rise of immunotherapy in HCC, deeper researches, managing to acquire individualized TIDE score based on our indigenous and clinical HCC sample, are worth carrying out to identify HCC patients who could benefit from anti-PD-1/ PD-L1/CTLA-4 immunotherapy.